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Abstract
Duchenne muscular dystrophy (DMD) is a genetic disorder caused by the absence of dystrophin in both skeletal and cardiac
muscles. This leads to severe muscle degeneration, and dilated cardiomyopathy that produces patient death, which in most
cases occurs before the end of the second decade. Several lines of evidence have shown that modulators of nitric oxide
(NO) pathway can improve skeletal muscle and cardiac function in the mdx mouse, a mouse model for DMD. Whole body
periodic acceleration (pGz) is produced by applying sinusoidal motion to supine humans and in standing conscious rodents
in a headward-footward direction using a motion platform. It adds small pulses as a function of movement frequency to the
circulation thereby increasing pulsatile shear stress to the vascular endothelium, which in turn increases production of NO.
In this study, we examined the potential therapeutic properties of pGz for the treatment of skeletal muscle pathology
observed in the mdx mouse. We found that pGz (480 cpm, 8 days, 1 hr per day) decreased intracellular Ca2+ and Na+
overload, diminished serum levels of creatine kinase (CK) and reduced intracellular accumulation of Evans Blue.
Furthermore, pGz increased muscle force generation and expression of both utrophin and the carboxy-terminal PDZ ligand
of nNOS (CAPON). Likewise, pGz (120 cpm, 12 h) applied in vitro to skeletal muscle myotubes reduced Ca2+ and Na+
overload, diminished abnormal sarcolemmal Ca2+ entry and increased phosphorylation of endothelial NOS. Overall, this
study provides new insights into the potential therapeutic efficacy of pGz as a non-invasive and non-pharmacological
approach for the treatment of DMD patients through activation of the NO pathway.
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Introduction
Duchenne muscular dystrophy (DMD) is a X-linked recessive
and progressive muscle disease caused by failure to express
sarcolemmal protein dystrophin [1,2]. DMD is the most common
muscular dystrophy observed in children. The estimated world-
wide incidence of DMD is approximately 1:3500 male live births
[3]. Dystrophin is a key component of the dystrophin glycoprotein
complex (DGC), which links the cytoskeleton of the muscle fibers
to the extracellular matrix [1,2,4]. In the absence of dystrophin,
DGC is functionally impaired such that mechanical stress
associated with contraction leads to the degeneration of muscle
fibers [5,6]. It is now well established that the lack of dystrophin
expression in skeletal and cardiac mdx muscles leads to several
secondary processes including inflammation, alteration of intra-
cellular ion homeostasis, chronic degeneration and regeneration
and necrosis/apoptosis of muscle fibers, metabolic alterations and
interstitial fibrosis all of which exacerbate the progression of DMD
[7].
Cumulative evidence suggests that in addition to its mechanical
function as a molecular scaffold, dystrophin plays an important
signaling role in both cardiac and skeletal muscles [8]. Thus, the
absence of dystrophin is associated with intracellular Ca2+ and Na+
overload in DMD patients [9] and mdxmice [10,11], alterations in
transient receptor potential channel function (TRPC) [12] and
activation of several Ca2+-dependent intracellular signaling
pathways in skeletal muscle [10,11,13].
Although the genetic defect responsible for DMD was identified
decades ago [4], currently there is no effective treatment available
for this devastating disease. Administration of corticosteroids and
related drugs to diminish inflammation in DMD [14] have limited
efficacy along with significant side effects, such as respiratory
muscle weakness, hypoxemia, fatigue, and hypoventilation during
sleep [15–17]. The need for new treatments have led investigators
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to focus on multiple therapeutic strategies such as gene and cell
based therapies designed to bypass the mutation (exon skipping) or
to replace the missing gene and/or dystrophin protein, which have
achieved varying degrees of success [18,19]. Although such
treatments are in clinical trials, new pharmacological strategies
appear promising and can circumvent many of the difficulties
obstructing gene and cell based therapies [20]. In general, the new
pharmacological strategies aim to decrease inflammation, reduce
the intracellular Ca2+ overload, enhance NO production by
providing NO precursors, administer NO donors, or phosphodi-
esterase type-5A (PDE5A) inhibitors [20–24] and/or upregulating
utrophin, a compensatory protein whose molecular structure is
similar to dystrophin. Thus, there is need for a successful approach
that enables patients to survive, improve the quality of life, and
thus take advantage of gene therapies when they eventually
become available.
pGz is a non-invasive, drug-free approach to enhancing NO
pathways, which is produced by applying sinusoidal motion to
supine humans and in standing conscious rodents in a headward-
footward direction using a motion platform that adds small pulses
to the circulation, thereby increasing pulsatile shear stress to the
vascular endothelium [25]. Shear stress and pulsatile shear
represents the tangential frictional force and axial forces exerted
on the luminal walls of the vascular system by the blood flow and
are potent regulators of endothelial and neuronal nitric oxide
synthase expression (eNOS and nNOS. also referred to as
constitutive NOS or cNOS), and of NO production in vitro and
in vivo.
The aim of the current study was to explore the potential
therapeutic effect of pGz in the mdx mouse model of DMD. We
found that pGz treatment caused significant decrease of intracel-
lular Ca2+ and Na+ overload, reduced sarcolemmal Ca2+ entry,
diminished serum CK levels, and reduced intracellular accumu-
lation of Evans Blue. Furthermore, pGz improved muscle force
generation and up-regulation of both utrophin and the carboxy-
terminal PDZ ligand of nNOS (CAPON). These effects were also
associated with transient increase in phosphorylation of eNOS.
Overall, this study provides new insights about the potential
therapeutic utility of pGz to treat patients suffering from DMD.
Materials and Methods
Myotube cultures
Primary myoblasts were isolated from hind limbs muscles from
wild type (wt) C57BL/10 and mdx male mice as described
previously [10]. Myotubes were differentiated in differentiation
media (low glucose DMEM, 4% horse serum) for 3 days and then
subjected to pGz inside a humidified incubator at 37uC, 5% CO2
and 10% O2. Control dishes with non-treated myotubes were
maintained at the same incubator. To study the participation of
cNOS in pGz signaling pathway we treated myotubes with or
without 1 mM N-(G)-nitro-L- arginine methyl ester (L-NAME,
Sigma-Aldrich, MO, USA).
Animals
Male 6-week old C57BL/10 and mdx mice were obtained from
the Jackson Laboratory (ME, USA). All animals were housed at
23uC with 12 h light-dark cycle and maintained with standard
mouse chow and water ad-libitum.
pGz in vivo and in vitro
The in vivo pGz treatment was performed on unanesthetized
restrained 6-week old wt and mdx mice using a reciprocal platform
(Scilogex, SK-180-Pro, CT, USA) set at a frequency of 480 cpm,
Gz60.3 m/sec2, over a one-hour daily for 8 days. After pGz
treatment, animals were returned to their cages in the animal
facility. All experiments were carried out 4 h after the last pGz
treatment. At the conclusion of the treatment, mice were driven to
the laboratory installation to perform the experiments described
bellow. The in vitro pGz treatment was carried out in wt and mdx
myotubes placed in an incubator (10% O2 and 5% CO2 at 37uC)
and mounted in a reciprocal platform (described above) set at a
frequency of 120 cpm for 12 h. Untreated myotubes were kept in
the same incubator.
Ca2+ and Na+ selective microelectrodes
Double/barreled Ca2+-selective and Na+-selective microelec-
trodes were prepared as described previously [26]. The Ca2+
ionophore II-ETH 129 or the Na+ Ionophore I-ETH 227 (both
Fluka Sigma-Aldrich, MO, USA) were used to back-fill the Ca2+
and Na+-selective microelectrodes, respectively. Each ion-selective
microelectrode was individually calibrated as described previously
[26]. After making measurements of intracellular resting Ca2+
([Ca2+]i) and resting Na
+ concentration ([Na+]i) all microelectrodes
were recalibrated, and if the two calibration curves did not agree
within 3 mV, data from that microelectrode were discarded.
Recording of [Ca2+]i and [Na
+]i in muscle fibers and
cultured myotubes
Measurements of [Ca2+]i, and [Na
+]i, were performed both
in vivo, in anesthetized (ketamine 100/xylazine 5 mg/kg) wt and
mdx mice muscle fibers and in vitro on differentiated wt and mdx
myotubes. For in vivo measurements, once the animal was
anesthetized, a small incision was made in the skin, the muscle
fascia was removed and the superficial fibers of Vastus lateralis (left
leg) were exposed. A rectal temperature probe was placed,
connected to a low noise heating system for maintaining animal
body temperature during experimental procedures (WPI-
ATC1000, FL, USA). The superficial muscle fibers were perfused
with imaging solution (in mM: 140 NaCl, 5 KCl, 2.5 CaCl2,
1 MgSO4, 5 glucose, and 10 Hepes/Tris, pH 7.4) and were
impaled with either the Ca2+ or Na+ double-barreled microelec-
trode. The membrane potential signal (Vm), the Ca
2+ potential
(VCaE) and the Na
+ potential (VNaE) were recorded via a high
impedance amplifier (WPI Duo 773 electrometer WPI, FL, USA).
The potential from the Vm barrel (3 M KCl) was subtracted
electronically from VCaE or VNaE, to produce a differential Ca
2+-
specific (VCa) or Na
+ specific (VNa) potential that represents
[Ca2+]i, or [Na
+]i based on an experimental calibration curve
performed with the same electrode. Vm, VCa and VNa were filtered
with a low pass filter (30–50 KHz) to improve the signal-to noise
ratio and stored in a computer for further analysis. For in vitro
studies, cells were maintained in imaging solution and impaled
with either a double-barreled Ca2+- or Na+- selective microelec-
trode and the procedures to obtain the specific potential for Ca2+
(VCa) or Na
+ (VNa) were identical to that described above.
Forelimb grip strength test
Forelimb grip strength was assessed by means of a grip strength
meter (Columbus Instruments, OH, USA). Wt and mdx mice were
lifted over the baseplate by the tail so that its forepaws were
allowed to grasp onto the steel grid. The mouse was then gently
pulled back by the tail until its grip was released. Mice were tested
5 times, with one-minute interval between trials. The three highest
measured values were averaged to calculate the grip strength,
which was normalized by the body weight in grams.
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In situ muscle function measurements
Mice were deeply anesthetized via intraperitoneal (i.p.) injection
of ketamine-xylazine mixture (80 and 10 mg/kg) and carefully
monitored throughout the experiment. Additional doses were
administered as needed to ensure no reflex response to toe pinch.
The distal tendon of the Tibialis Anterior (TA) muscle was
dissected free from surrounding tissue, individually tied with 4.0
braided surgical silk, and then cut at the most distal end. The
sciatic nerve was exposed, and all its branches were cut except for
the common peroneal nerve. The foot was secured to a platform,
and the knee was immobilized using a stainless steel pin. The TA
tendon was attached to the lever arm of a 305B dual-mode
servomotor transducer (Aurora Scientific, ON, Canada). TA
muscle contractions were then elicited by stimulating the distal
part of the sciatic nerve via bipolar electrodes, using supramaximal
square-wave pulses of 0.02 ms (701A stimulator; Aurora Scientif-
ic). Data acquisition and control of the servomotors were
conducted using a LabVIEW-based DMC program (version
5.202; Aurora Scientific, ON, Canada). The muscle length was
measured using digital calipers based on well-defined anatomical
landmarks. The optimal muscle length (Lo) was determined by
incrementally stretching the muscle using micromanipulators until
the maximum isometric twitch force was achieved. Three
maximum isometric tetanic forces (Po) were determined using a
train of 150-Hz, 500-ms supramaximal electrical pulses at the Lo
in the muscle, and the highest Po was recorded. A 2-minute resting
period was allowed between each tetanic contraction. The
normalized tetanic specific force (N/g) was calculated by dividing
Po by the muscle weight.
Serum Creatine Kinase determinations
Blood samples were obtained from anesthetized wt and mdx
mice by cardiac puncture [11]. Briefly, blood was collected in
sterile 1.5 mL eppendorf tube, allowed to clot in ice for 30 min
and then centrifuged at 3000 rpm for 10 minutes. Creatine kinase
(CK) levels were determined using the UV-kinetic method (Teco
Diagnostics, CA, USA) according to the manufacturers instruc-
tions. DAbsorbance/min were used to calculate CK enzymatic
activity and the results were expressed as International Kilo Units
per liter (KUI/L).
Evans Blue uptake
To assess muscle damage, Evans Blue dye (EBD) was used as a
marker of permeabilized or damaged muscle fibers. EBD was
dissolved in PBS (10 mg/mL) and sterilized by filtration through
0.2 mm filters. Dystrophic mdx mice with or without 8 days of pGz
treatment were i.p. injected with 0.5 mg dye per 10 g body weight
(n = 2 per group). Six hours later, mice were euthanized, the skin
was removed, and the animals were photographed and inspected
for dye uptake into skeletal muscles, indicated by blue coloration.
Western blot protein expression analysis
Gastrocnemius muscles were dissected and minced with a pair
of scissors and then homogenized with an electric homogenizer
(LabGEN 7b, Cole-Parmer, IL, USA) in modified RIPA buffer
(150 mM NaCl, 50 mM Tris pH=7.4, 1% Triton X-100, 0.5%
Na deoxycholate, 0.1% SDS, 5 mM EDTA, 2 mM EGTA, 1X
Roche Complete Protease Inhibitor and 1x Roche PhosSTOP).
Myotubes were pGz-treated, quickly washed with ice-cold PBS,
and lysed with modified RIPA buffer. Total lysates were incubated
in ice for 30 min and then spun down by centrifugation at
16,0006g for 20 min. Total protein concentrations were deter-
mined using the BCA method (Thermo Scientific, IL, USA). The
extracts were then heated for 5 min in Laemmli loading buffer
with 50 mM DTT and 25–50 mg were separated by SDS-PAGE
4–15% gradient gels (Bio-Rad) and transferred to PVDF
membranes for immunoblotting. Membranes were blocked with
SEA Blocking Buffer (Thermo Scientific, IL, USA) for 1 h. The
following primary antibodies were purchased from BD Transduc-
tion Labs (CA, USA): anti-utrophin (#610896, 1:1000), anti-
eNOS (#610296, 1:1000). Anti-CAPON (#ab90854 1:1000),
anti-phospho-(Ser632)-eNOS (#ab76199, 1:1000) were obtained
from ABCAM (MA, USA). Anti-nNOS (#4236S, 1:1000), anti-
IkBa (#4814P, 1:1000), anti-NF-kB p65 (#8242P, 1:1000) and
GAPDH (#2118S, 1:5000) were purchased from Cell Signaling
(MA, USA). Primary antibodies were diluted in blocking buffer
with 0.1% Tween-20, incubated overnight at 4uC, and then
washed with TBS 0.1% Tween-20 (TBS-T). Primary antibodies
were exposed with either anti-mouse IRDye 680 nm or anti-rabbit
IRDye 800 nm antibodies (Li-COR Biosciences, NE, USA),
washed, and then quantified with an Odyssey Imaging System
(Li-COR Biosciences, NE, USA). Protein levels were normalized
to GAPDH expression.
Resting Sarcolemmal Cation entry
Sarcolemmal Ca2+ entry rates were estimated by the rate of dye
quench by Mn2+ entry in myotubes loaded with 5 mM Fura-2-AM
as described previously [26]. Briefly, cells were exited at the
isosbestic wavelength for Fura-2 (357/7 nn) and fluorescence
emission at 510 nm was then captured from regions of interest
within each myotube. Rate of Ca2+ entry were estimated from the
slope of the quenched signal and expressed as fluorescence
arbitrary units per second (f.a.u/s).
Ethics approval
All procedures for animal experimentation were done in
accordance with guidelines approved by the Animal Care and
Use Committee (IACUC) at University of California at Davis
(Protocol number: #17298), Brigham and Women’s Hospital
Harvard Medical School (Protocol number: #23456), University
of Pennsylvania (Protocol number: #803950) and Mount Sinai,
Medical Center (Protocol number: #14-22-A-04).
Statistical analysis
All values are expressed as mean 6 SEM. Statistical analysis
was performed using two-tailed unpaired t-test, or one-way
analysis of variance coupled with either Tukey’s or Dunnett t-
test for multiple measurements to determine significance (P,0.05).
Results
pGz reduces [Ca2+]i and [Na
+]i in vivo in mdx muscles
It is well documented that skeletal muscle from mdx mice and
DMD patients have significantly elevated [Ca2+]i [8–11,27] and
[Na+]i [13,28,29]. Since Ca
2+ and Na+ overload are hallmarks of
the mdx and DMD pathology, we studied the effects of pGz
treatment on [Ca2+]i and [Na
+]i measured in vivo in the
superficial fibers of Vastus lateralis muscles from both wt and
mdx mice. As showed in Figure 1A, mdx muscles have a [Ca2+]i
that is significantly higher than those of wt muscles (390612 nM
vs 12163 nM, P,0.001). However, after pGz treatment mdx
muscle fibers showed a significant reduction in the [Ca2+]i to
19863 nM (P,0.001), while no significant effect was observed in
wt muscles (12163 nM, P.0.05) (Figure 1A). Likewise, [Na+]i
was significantly elevated in mdx muscles compared with wt
muscles (18.160.2 vs 8.060.1 mM, P,0.001) (Figure 1B). pGz
treatment significantly reduced [Na+]i to 10.160.2 mM in
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dystrophic muscles (P,0.001), without any significant effect in wt
muscles (7.560.1 mM, P,0.001) (Figure 1B).
Muscle strength is improved by pGz treatment in mdx
mice
Both DMD patients and mdx models are characterized by
muscle weakness as the result of progressive muscle damage [7].
To establish if pGz treatment improves muscle force in dystrophic
muscles, forelimb grip strength and tetanic specific force,
developed in situ in Tibialis Anterior (TA) muscles, were
measured. Comparison of normalized forelimb grip strength
values (Figure 2A) revealed that mdxmice had a 46% reduction on
grip strength compared to wt mice (P,0.001). After pGz
treatment, mdx mice had normalized values of forelimb grip
strength that were similar to those of untreated wt mice
(Figure 2A). Similar results were observed in measurements of
in situ tetanic specific force in TA muscles. In untreated mdx mice
tetanic specific force was significantly decreased in the TA muscles
compared with wt mice (22.060.8 vs 34.960.7 N/g, P,0.001).
pGz treatment for 8 days significantly improved TA in situ tetanic
specific force (26.361.1 N/g, P,0.05 vs untreated mdx mice)
(Figure 2B). These data show that pGz improves muscle function
in mdx mice, possibly due to a reduction in muscle destruction.
Reduction of muscle damage by pGz in dystrophic mice
To test the hypothesis that pGz reduces muscle damage in
dystrophic muscles serum CK levels and Evans Blue dye (EBD)
uptake in skeletal muscles were measured. Figure 2C shows that
serum levels of CK in untreated mdx mice were significantly
elevated in comparison to wt mice (14.561.9 vs 0.560.2 KUI/L,
P,0.001). pGz treatment significantly reduced CK levels in mdx
mice compared with mdx without treatment (8.861.2 KUI/L, P,
0.05) (Figure 2C).
To test for increased sarcolemmal permeability pGz-treated and
untreated mdx mice were i.p. injected with EBD and euthanized
after six hours to obtain dye uptake. EBD is a marker of damaged
and permeable muscle fibers in mouse models of muscular
dystrophy and as an endpoint in therapeutic trials [30]. Figure 2D
shows that mdx mice have extensive zones of intense EBD uptake
(dark blue staining) in all muscle groups in the ventral, dorsal and
lateral views of the hindlimbs. High levels of dye uptake in the
abdominal area were observed in both untreated and pGz-treated
groups, most likely the result of the i.p. injection of EBD.
However, under the same experimental conditions, pGz-treated
mice showed much lower levels of EBD uptake in all muscle
groups. These results suggest that pGz treatment significantly
decreased membrane permeability and muscle damage in mdx
muscle.
Expression of Utrophin and CAPON is enhanced by pGz
Several studies in the mdx mouse model have demonstrated that
overexpression of utrophin (an autosomal dystrophin homologue)
and/or carboxy-terminal PDZ ligand of nNOS (CAPON)
improves dystrophic muscle pathology [31–33]. Furthermore,
systemic administration of NO precursors has been reported to
increase utrophin and CAPON levels in mdx muscles [33–35]. To
determine whether the effect of the pGz treatment observed in
dystrophic muscles was associated with up-regulation of utrophin
and/or CAPON, the expression of both proteins in gastrocnemius
muscles from non-treated and pGz-treated mdx mice was
measured with Western blot analysis. Figure 3A shows that pGz
treatment significantly increased utrophin protein levels by 2.1-
fold in mdx mice related to untreated-mdx mice (P,0.01).
Likewise, CAPON was significantly up-regulated by 2.2-fold after
pGz treatment compared to untreated mdx mice (P,0.05)
(Figure 3B).
pGz increases IkBa expression in mdx muscles
Treatment with NO precursors, like L-arginine has been shown
to reduce the inflammation and the activity of NF-kB as well as an
increases in IkB-a expression in mdx muscles [35]. We studied
protein expression levels of p65 (major NF-kB subunit) and IkB-a
(NF-kB repressor) by Western blot in the gastrocnemius of pGz-
treated and untreated wt and mdx mice. There was a 2.7-fold
increase in p65 expression and 1.8-fold increase in IkB-a
expression in untreated mdx muscles compared with wt muscles
(P,0.01) (Figure 4). Whereas pGz did not have any significant
effect on p65 expression in either wt or mdx muscles (P.0.05),
pGz treatment increased IkB-a by 52% in mdx mice (P,0.05),
without significant change in wt muscles (P.0.05) (Figure 4).
These data suggest a reduction in the inflammatory NF-kB
pathway due to a reduction in IkB-a degradation, in dystrophic
muscles treated with pGz.
Decreases in [Ca2+]i and [Na
+]i by pGz in mdx myotubes
Due to the complexity of the multi-systemic response to pGz in
dystrophic mice, cultured myotubes were used as an in vitro
model to study the mechanisms of mechano-transduction in
skeletal muscle cells. Intracellular ion dysfunction, a hallmark of
dystrophic pathology, was taken as an endpoint for the effect of
pGz in skeletal muscle cells. Myotubes isolated from wt and mdx
mice were exposed to pGz and then [Ca2+]i, and [Na
+]i were
measured. Similar to the result in muscle fibers, significant
differences in both [Ca2+]i and [Na
+]i were observed between wt
and mdx myotubes (Figure 5). Furthermore, whereas pGz
treatment showed no measurable effects on either [Ca2+]i
(11661 vs 11561 nM, P.0.05) or [Na+]i (8.160.1 mM vs
8.260.1 mM P.0.05) in wt myotubes, it significantly reduced
both [Ca2+]i (32363 to 20362 nM) and in [Na
+]i (15.760.6 to
10.760.4 mM) in mdx cells (Figure 5). These data reveal that pGz
treatment in vitro provides similar beneficial effects in myotubes to
those observed in dystrophic muscles in vivo, suggesting that pGz
effects are mediated by plasma membrane mechanoreceptors
under these experimental conditions, and that myotubes are a
Figure 1. pGz reduces muscle [Ca2+]i and [Na
+]i in vivo in mdx
mice. Mice were treated daily for 8 days with pGz (480 cpm, 1 h).
Animals were anesthetized and ion concentrations were measured
in vivo in superficial fibers of the vastus lateralis. A. [Ca2+]i measure-
ments B. [Na+]i measurements. Data are expressed as mean 6 S.E.M.
from n fibers in N mice, ***P,0.001, ANOVA-Tukey’s.
doi:10.1371/journal.pone.0106590.g001
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reliable in vitro model for the study of the signaling pathways of
muscle dystrophy.
Reduction of resting sarcolemmal Ca2+ entry by pGz in
mdx myotubes
To explore if pGz reduces the abnormal sarcolemmal Ca2+
entry that has been observed previously in mdx skeletal muscle
cells [10], we examined the rate of Fura-2 fluorescence quench by
Mn2+ to quantify the levels of Ca2+ entry in dystrophic myotubes.
The Mn2+-quench studies indicated that untreated mdx myotubes
have a significantly increased rate of resting Ca2+ entry compared
to wt myotubes (47% increase, P,0.001) and that treatment with
pGz was able to reduce resting Ca2+ entry to levels similar to that
of wt (Figure 6). These data demonstrate that pGz treatment
decreased the [Ca2+]i, in part, due to a reduction in the Ca
2+ entry
from the extracellular space in dystrophic myotubes.
pGz increases eNOS phosphorylation in dystrophic
muscle cells
Beneficial effects of pGz in skeletal muscle have been associated
with eNOS activation [36]. Therefore, here we studied the effect
of pGz treatment in the time course of eNOS activation in
Figure 2. pGz increases muscle strength and reduces muscle damage in mdx mice. A. Averaged forelimb grip strength normalized to body
weight evaluated after 8 days of pGz treatment. B. In situ tetanic specific force measured in Tibialis Anterior after 8 days of pGz treatment. C. Serum
Creatine Kinase (CK) measurements and D. Evans blue uptake in skeletal muscles from both untreated and pGz-treatedmdxmice. Data are expressed
as mean 6 S.E.M. from N mice, *P,0.05 and ***P,0.001, unpaired two-tailed t-test.
doi:10.1371/journal.pone.0106590.g002
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dystrophic myotubes, measured by phosphorylation at Ser632.
Cultured mdx myotubes were exposed to pGz for increasing
amounts of time and then quickly lysed and subjected to Western
blot analysis. As showed in Figure 7A, pGz causes a transient
increase in eNOS phosphorylation with significant activation after
the first 30 min of treatment, reaching a maximum value (1.760.2
fold relative to basal levels) after 1 h of treatment, which is
followed by a decline to untreated levels by 3 h of treatment.
To further assess the contribution of eNOS on pGz-mediated
reduction of [Ca2+]i, dystrophic myotubes were pre-incubated
with L-NAME (1 mM) for 30 min and then treated with pGz. L-
NAME was kept in the media for the entire experiment for both
the untreated and pGz-treated group. pGz treatment significantly
reduced the [Ca2+]i from 31165 to 15365 in mdx myotubes (51%
reduction, P,0.001), however L-NAME treatment almost com-
pletely blunted its ability to lower [Ca2+]i (Figure 7B). Since, L-
NAME blocks all cNOS, we can not discard the potential
participation of nNOS in the pGz-induced [Ca2+]i reduction
observed in dystrophic myotubes even though its expression in
down regulated due to lack of dystrophin.
Expression of eNOS and nNOS in pGz-treated mdx
muscles
pGz treatment is associated with an increase in total nNOS and
eNOS protein expression in endothelial cells and cardiac muscle
[37]. To further study the role of nNOS and eNOS pathways in
the effects of pGz on skeletal muscles we studied the expression
levels of both proteins in wt and mdx mice subjected to pGz
treatment. Figure 8A shows representative Western blot analysis of
eNOS and nNOS expression in wt and mdx gastrocnemius
muscles with and without pGz treatment. Average normalized
data indicate that that pGz treatment increased eNOS expression
by 24% compared to untreated-mdx muscles, but did not reach
statistical significance (P.0.05, Fig. 8B) without any detectable
effect on the expression of nNOS (P.0.05, Figure 8C).
Discussion
Despite of the identification of the molecular defect responsible
for DMD several decades ago, there are still no effective cures for
the disease. There remains a profound need for alternative
therapeutic strategies that can improve muscle strength, amelio-
rate the dystrophic pathology, and enhance patient quality of life.
Here we have examined the benefit of pGz, an enhancer of NO
signaling, to treat the mdx mouse, a DMD experimental model
[38–40]. pGz is a non-invasive, drug free approach, which is
produced by applying sinusoidal motion to a supine body in a
Figure 3. Utrophin and CAPON protein levels in muscles from
pGz-treated mdx mice. After 8 days of pGz treatment mice were
euthanized and the gastrocnemii were dissected and homogenized for
western blot analysis. Representative western blots and quantifications
of utrophin (A) and CAPON (B) expression. Each lane in the western blot
represents a muscle sample obtained from a different mouse. Data
were normalized to GAPDH. Data are expressed as mean 6 S.E.M. from
N mice, *P,0.05 and **P,0.01, unpaired two-tailed t-test.
doi:10.1371/journal.pone.0106590.g003
Figure 4. pGz reduces the activation of the NF-kB pro-
inflammatory pathway in dystrophic muscles. Total p65 and
IkB-a was measured by western blot in gastrocnemii from untreated
and pGz-treated mice. A. Representative western blot. B. Quantification
of p65 and C. IkB-a. Data were normalized to GAPDH. Each lane in the
western blot represents a muscle sample obtained from a different
mouse. Data are expressed as mean 6 S.E.M. from N mice, *P,0.05 and
**P,0.01, ANOVA-Tukey’s.
doi:10.1371/journal.pone.0106590.g004
Figure 5. pGz reduces [Ca2+]i and [Na
+]i in mdx myotubes.
Myotubes were treated with pGz (120 cpm, 12 h) and ion concentra-
tions were measured using double-barreled ion selective microelec-
trodes. A. [Ca2+]i and B. [Na
+]i determinations. Data are expressed as
mean 6 S.E.M. ***P,0.001, ANOVA-Tukey’s.
doi:10.1371/journal.pone.0106590.g005
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headward-footward direction using a motion platform [39],
causing additional pulses to the circulation, increasing pulsatile
shear stress to the vascular endothelium and the release of NO
[41]. Previous studies have shown that NO therapy has beneficial
effects in dystrophic mouse models [22,34,35]. Thus, diverse NO-
based therapies have been developed to restore intracellular NO
homeostasis in mdx muscle, like treatment with L-arginine a
substrate of nitric oxide synthase for NO synthesis [42], NO
donors [43,44] and more recently to amplify the NO-cGMP
signaling pathways with phosphodiesterase (PDE5A) inhibitors.
Thus, pGz represent a new and safe therapeutic option for the
treatment of DMD based on activation of NO signaling pathway.
We have found that treatment of mdx mice with pGz for even a
short period of time (8 days) significantly reduced the intracellular
Ca2+ and Na+ overload previously reported by us and others
[8,10,11,13,27] both in vivo in muscle fibers from mdx mice and
in cultured mdx myotubes. Ca2+ and Na+ overload have been
shown to be deleterious to skeletal muscle fibers, and are
associated with either necrotic or apoptotic cell death [29,45].
These results suggest that the benefits of pGz would not only arise
from paracrine effects of the surrounding endothelium but also
from direct effects on the muscle cells, possible through activation
of mechanoreceptors. Examination of other cell types has also
Figure 6. Resting rate of Mn2+ quench of Fura-2 fluorescence in
pGz-treated mdx myotubes. A. Representative traces and B. average
resting rates of Mn2+ quench. Data are expressed as mean 6 S.E.M.
**P,0.01, ***P,0.001, ANOVA-Tukey’s.
doi:10.1371/journal.pone.0106590.g006
Figure 7. pGz activates eNOS in dystrophic myotubes. A. Myotubes were treated with pGz (120 cpm, 12 h) for the indicated times, quickly
lysed in modified RIPA buffer and eNOS phosphorylation (Ser632) was assessed by western blot. B. L-NAME treatment blocks the pGz-induced
reduction of [Ca2+]i in mdx myotubes. Data are expressed as mean 6 S.E.M. *P,0.05, **P,0.01, ***P,0.001, ANOVA-Dunnett’s (A) and Tukey’s. (B).
doi:10.1371/journal.pone.0106590.g007
Figure 8. nNOS and eNOS protein levels in muscles from pGz-
treated mice. Gastrocnemius were dissected, homogenized and
protein expression was assessed by western blot. A. Representative
western blot. B. Quantification of eNOS and C. nNOS. Each lane in the
western blot represents a muscle sample obtained from a different
mouse. Data were normalized with GAPDH. Data are expressed as mean
6 S.E.M. from N mice, *P,0.05, and ***P,0.001, ANOVA-Tukey’s.
doi:10.1371/journal.pone.0106590.g008
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shown that mechanical activity may also be a positive regulator of
NOS activity and/or expression and therefore NO production.
For example, shear stress applied to endothelial cells in vitro
induces an increase in eNOS mRNA and protein levels [46,47].
Similarly, compressive loads applied to bones or cyclic strains
applied to osteoblasts or osteocytes stimulate NOS activity [48].
Thus, it is possible that outside vessel luminal walls the pGz
signaling cascade may be activated through cellular mechano-
transduction, mechanism by which cells convert mechanical
signals into biochemical responses, increasing physiological NO
production by modulating cNOS activity.
In addition, our study indicates that pGz induced a significant
reduction in resting sarcolemmal Ca2+ entry in cultured mdx
myotubes. Dystrophic muscle cells are characterized by increased
activity of transient receptor potential channels (TRPC), up-
regulation of the reverse mode of Na+/Ca2+ exchanger (NCX1)
[13] and hyper-nitrosylation of RyR1 [49] all processes known to
either directly or indirectly modulate sarcolemmal Ca2+ fluxes.
Thus, a reduction in cationic influx induced by pGz tends to
restore the intracellular Ca2+ and Na+ homeostasis in mdx muscle
cells.
Although, we do not precisely know the mechanisms by which
pGz improves Na+ and Ca2+ homeostasis in mdx cells it is possible
that this could be linked to the increased expression of utrophin
and CAPON. Our experimental findings demonstrated that pGz
treatment increased utrophin expression in mdx muscles by 2.1-
fold which provide membrane stabilization, and CAPON by 2.2-
fold which might restore nNOS localization to the sarcolemma, a
key criterion for normal NO synthesis in skeletal muscle [33].
Utrophin is slightly smaller than dystrophin (395 kDa) and its
primary structure is very similar to that of dystrophin, particularly
in the N- and C-terminal ends that bind other proteins.
Transgenic overexpression of utrophin in mdx mice has been
shown to improve muscle function [50,51]. On the other hand,
CAPON expression has been associated to an increased in NOS
activity and nNOS expression, previously identified as treatments
that reduce disease severity in mdx mice [52,53]. In muscle cells,
the localization of nNOS is impaired in the absence of dystrophin,
which impacts muscle function, satellite cell activation and NO
production [5,54]. In neurons, the adaptor protein CAPON
regulates nNOS localization and activity [55,56]. CAPON
expression has been previously demonstrated in skeletal muscles,
and its expression is increased in regenerating skeletal muscle cells
[33]. Furthermore, in cardiomyocytes CAPON overexpression
induced up-regulation of nNOS and enhanced intracellular NO
production, which could both be blocked by treatment with L-
NAME [57]. It is very likely that utrophin and CAPON
overexpression may have some positive impact on mdx muscle
cells including a decrease of sarcolemmal Ca2+ and restitution of
nNOS localization to the sarcolemma. Further experiments need
to be carried out to clarify this issue in pGz-treated skeletal muscle
cells.
Muscle from dystrophic mice demonstrated muscle weakness
compared with muscles from wt mice of the same age. Decrements
in force generation in dystrophic muscle could have resulted from
muscle plasma membrane fragility, impairments in the steps of
excitation-contraction coupling, and/or altered contractile protein
function in mdx muscle [58]. Furthermore, dystrophic skeletal
muscle cells have a diminished SR Ca2+ loading due to RyR1 and
IP3R leak at resting conditions [10] and a reduced Ca
2+ transient
elicited by membrane depolarization [59,60]. All of theses factors
may compromise muscle force generation in mdx mice. Mdx
muscles subjected to pGz treatment displayed increased forelimb
grip strength and a significant improvement of TA specific force.
The study presented here is the first to directly test the ability of
pGz to improve skeletal muscle strength in dystrophic mice by
performing in vivo force measurements in the TA. These results
are consistent with the hypothesis that a normalization of [Ca2+]i
by pGz treatment might improved excitation-contraction cou-
pling, decreased muscle damage and/or increased muscle
regeneration and thereby force generation in dystrophic muscles.
Further research is required to elucidate the mechanisms
responsible by which pGz enhances muscle force in mdx muscle
fibers.
In addition, it has been reported that pGz improves muscle
recovery after eccentric exercise in human subjects [61]. Eccentric
arm exercises were carried out as 10 sets of 10 lengthening
contractions on a seated preacher curl bench using a dumbbell
(first day only), followed by 30 min of passive recovery, and
45 min pGz (140 cpm, 45 min per day). pGz treatment signifi-
cantly increased muscle strength recovery after eccentric exercise,
and attenuated CK response even though the reduction was not
statistically significant [61].
It is very well established that lack of dystrophin results in
fragibility of skeletal muscle fibers, due to loss of muscle fiber
membrane integrity, leading to dramatic muscle deterioration [7].
Our studies with EBD in pGz-treated mdx mice show a marked
reduction of dye incorporation in the majority of the hind limb
muscles. Moreover, pGz treatment significantly reduced serum
CK activity in mdx mice, another way to test plasma membrane
integrity, suggesting that it was responsible for a significant
reduction in membrane damage and permeability of the
dystrophic muscles.
Moreover, pGz increases expression of IkBa (1.5-fold), a
member of a family of cellular proteins that function to inhibit
the pro-inflammatory NF-kB transcription factor in mdx muscle
fibers. Similar results have been observed with L-arginine
treatment showing a decreased IkBa degradation in mdx
diaphragm [35]. It has been reported that resting intracellular
Ca2+ is indirectly implicated in NO production through the
modulation of the NF-kB pathway in mdxmice [10]. A decrease in
[Ca2+]i and a restoration of the NF-kB pathway, most likely via
regulation of NO intracellular homeostasis would ameliorate
muscle destruction in mdx muscle fibers.
Although the molecular mechanism by which pGz mitigates
muscle damage in mdx mice is still unknown, it is likely to involve
NO pathways. NO is gaseous messenger that conveys information
based on rates of production, localization and concentration
[62,63] and whose protective effect in DMD results from multiple
site of actions. Increases in NO signaling has been shown to reduce
muscle infiltration [35,64], decrease intracellular Ca2+ release
[65], reduce chronic elevation of [Ca2+]i in mdx cardiomyocytes
[66], increase the expression of cytoskeletal proteins in the integrin
complex [67] and utrophin and CAPON [33,42,65,68]. In the
present study we found that pGz increases eNOS phosphorylation
in mdx myotubes that peaked after 1 h, returning to a non-
significant level after 12 h. These results suggest that salutary effect
of pGz appears to be mediated through the NO signaling pathway
restoring the intracellular NO homeostasis in mdx muscle cells.
Moreover, L-NAME treatment blunted the pGz-mediated [Ca2+]i
reduction in mdx myotubes, showing that cNOS plays a role in the
downstream signaling pathways.
In summary, in this study we have demonstrated that pGz meets
several criteria for promising an effective therapy for DMD. These
conclusions are supported by the fact that pGz was efficient in
correcting the intracellular ion dyshomeostasis and the enhanced
Ca2+ entry in mdx muscle cells. Most importantly, pGz treatment
increased muscle strength measured by forelimb grip strength test
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and in situ force measurements in TA muscles. Furthermore, pGz
treatment significantly decreased muscle injury evidenced by a
reduction of Evans Blue incorporation in the limb muscles and a
decrease in serum CK levels. This reduction is most likely the
result of an increase in mechanical stabilization as a result of an
augmented expression in utrophin. Finally, the increase in
CAPON in mdx muscles may potentially improve intracellular
NO production by nNOS restitution to the plasma membrane.
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